{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:59:51Z","timestamp":1790449191795,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jaccao.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T16:01:24Z","timestamp":1600185684000},"page":"491-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting"],"prefix":"10.1016","volume":"2","author":[{"given":"Melissa Y.Y.","family":"Moey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna N.","family":"Tomdio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"McCallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul R.","family":"Naqash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blase A.","family":"Carabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2020.07.005_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2020.07.005_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2020.07.005_bib4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2020.07.005_bib5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib6","first-page":"1","article-title":"Immune checkpoint inhibitors-related cardiotoxicity","volume":"0","author":"Konala","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.jaccao.2020.07.005_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2020.07.005_bib8","doi-asserted-by":"crossref","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaccao.2020.07.005_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2020.07.005_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaccao.2020.07.005_bib11","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2020.07.005_bib12","first-page":"403","article-title":"Healthy North Carolina 2020: social determinants of health indicators","volume":"73","author":"Meyer","year":"2012","journal-title":"N\u00a0C Med J"},{"key":"10.1016\/j.jaccao.2020.07.005_bib13","doi-asserted-by":"crossref","first-page":"S1144","DOI":"10.1016\/j.jtho.2019.09.067","article-title":"P1.10 Inflammatory signature difference in rural urban and regional occupational exposure in lung cancer","volume":"14","author":"Sharma","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2020.07.005_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2020.07.005_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13104-016-2335-5","article-title":"What is the normal value of the neutrophil-to-lymphocyte ratio?","volume":"10","author":"Forget","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jaccao.2020.07.005_bib18","first-page":"182","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"Chitturi","year":"2019","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2020.07.005_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.jaccao.2020.07.005_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1 mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaccao.2020.07.005_bib21","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-019-0535-y","article-title":"Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors","volume":"7","author":"Awadalla","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2020.07.005_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients","volume":"23","author":"Sarocchi","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2020.07.005_bib24","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin T in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2020.07.005_bib25","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T\u2013Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2020.07.005_bib27","first-page":"702","article-title":"The neutrophil-to-lymphocyte ratio: a narrative review","volume":"10","author":"Faria","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jaccao.2020.07.005_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cardiores.2003.10.011","article-title":"Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury","volume":"61","author":"Vinten-Johansen","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2020.07.005_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the PD-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib30","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2020.07.005_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvs330","article-title":"CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE-\/- mice","volume":"97","author":"Ma","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2020.07.005_bib32","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib34","doi-asserted-by":"crossref","first-page":"e20583","DOI":"10.1200\/JCO.2019.37.15_suppl.e20583","article-title":"The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events","volume":"37","author":"Wakuda","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaccao.2020.07.005_bib36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","article-title":"Prednisone increases apoptosis in in\u00a0vitro activated human peripheral blood T lymphocytes","volume":"103","author":"Lanza","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaccao.2020.07.005_bib37","first-page":"861","article-title":"The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2018","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.jaccao.2020.07.005_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1634\/theoncologist.2016-0443","article-title":"Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy","volume":"22","author":"Scilla","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2020.07.005_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jaccao.2020.07.005_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087320301678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087320301678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:52:57Z","timestamp":1762973577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087320301678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2666087320301678"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2020.07.005","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}